



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 45/00		A2	(11) International Publication Number: WO 00/53224
			(43) International Publication Date: 14 September 2000 (14.09.00)
(21) International Application Number: PCT/EP00/02299		(74) Agent: BAUMBACH, Fritz; Robert-Rössle-Strasse 10, D-13125 Berlin (DE).	
(22) International Filing Date: 9 March 2000 (09.03.00)			
(30) Priority Data:		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, VZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
9905300.1 9 March 1999 (09.03.99) GB 9905307.6 9 March 1999 (09.03.99) GB 9905310.0 9 March 1999 (09.03.99) GB 9905314.2 9 March 1999 (09.03.99) GB 9905315.9 9 March 1999 (09.03.99) GB			
(71) Applicant (for all designated States except US): MAX-DELBÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN [DE/DE]; Robert-Rössle-Strasse 10, D-13125 Berlin (DE).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): ANKER, Stefan [DE/DE]; Hedrichplatz 25, D-10367 Berlin (DE). COATS, Andrew [AU/GB]; 105 A Cadogan Gardens, London SW3 2RF (GB). VOLK, Hans-Dieter [DE/DE]; Rathausstrasse 11, D-10178 Berlin (DE). RAUCHHAUS, Mathias [DE/DE]; Advokatenweg 40, D-06114 Halle (DE). SCHUMANN, Ralf, Reiner [DE/DE]; Buchenallee 104, D-16341 Zepernick (DE).		<i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: THERAPY AND USE OF COMPOUNDS IN THERAPY			
(57) Abstract			
<p>A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.</p>			